Search Results for citation:"90 FR 5900"

The Food and Drug Administration (FDA) issued a notice about withdrawing a previous announcement made on October 18, 2023, concerning a proposed study aimed at improving the quality of data for treatment centers. This decision was made because of issues related to the circumstances and timing of the study's execution. As a result, the FDA has canceled their plan to move forward with the study and withdrawn the previous notice. The withdrawal became effective on January 17, 2025.

The Food and Drug Administration (FDA) is inviting public feedback on its proposed collection of information related to adverse events and product experiences for FDA-regulated products. As part of fulfilling requirements under the Paperwork Reduction Act, the FDA seeks comments on whether this information collection is necessary, its accuracy, and ways to minimize the burden on respondents. They have updated forms and processes to standardize data collection, improve quality and clarity, and ensure confidentiality where necessary. The deadline for providing comments, either electronically or by mail, is March 18, 2025.